📷 Image: Wikimedia Commons / The U.S. Food and Drug Administration
Health
FDA Green‑Lights New Once‑Daily Cholesterol‑Lowering Pill
✍️ News18
🗓 18 Jul 2026, 05:12 AM
👁 3
The U.S. Food and Drug Administration has approved a new once‑daily medication that targets low‑density lipoprotein (LDL) cholesterol, offering a novel mechanism compared to existing therapies.
The FDA has officially approved a new once‑daily pill designed to lower LDL, or "bad," cholesterol levels in patients. The medication represents a fresh approach to lipid management, differing from the statin class that has dominated the market for decades.
Unlike statins, which inhibit cholesterol synthesis in the liver, the new drug works through a distinct pathway, potentially offering benefits for patients who experience side effects or inadequate response to current treatments. The approval follows extensive clinical trials that demonstrated significant reductions in LDL levels with a favorable safety profile.
The pill is intended for adults with elevated LDL cholesterol who are unable to achieve target levels with diet, exercise, or existing medications. Physicians will be able to prescribe it as part of a comprehensive cardiovascular risk reduction strategy.
Health experts anticipate that the new therapy could broaden treatment options for millions of Americans at risk of heart disease, especially those who have struggled with statin intolerance.
Unlike statins, which inhibit cholesterol synthesis in the liver, the new drug works through a distinct pathway, potentially offering benefits for patients who experience side effects or inadequate response to current treatments. The approval follows extensive clinical trials that demonstrated significant reductions in LDL levels with a favorable safety profile.
The pill is intended for adults with elevated LDL cholesterol who are unable to achieve target levels with diet, exercise, or existing medications. Physicians will be able to prescribe it as part of a comprehensive cardiovascular risk reduction strategy.
Health experts anticipate that the new therapy could broaden treatment options for millions of Americans at risk of heart disease, especially those who have struggled with statin intolerance.